What is ATRA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.10B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ATRA?

P/E (TTM) is n/a and 52-week range is $3.92 to $19.14 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ATRA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ATRA?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-1.00B, EPS (TTM) near $-1.18 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Atara Biotherapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Thousand Oaks, California, US, 9M shares outstanding, ISIN US0465132068 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Atara Biotherapeutics Inc

$ATRA

Health Care · Biotechnology

IR Run Scenarios

$9.48

+2.71%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 14 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Employees

Website

www.atarabio.com/

IPO

2014-10-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)